Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBT: 2010-2021

Historic EBT for Neurocrine Biosciences (NBIX) over the last 12 years, with Sep 2021 value amounting to $30.5 million.

  • Neurocrine Biosciences' EBT rose 153.42% to $30.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $58.1 million, marking a year-over-year decrease of 43.94%. This contributed to the annual value of $46.5 million for FY2019, which is 113.09% up from last year.
  • Per Neurocrine Biosciences' latest filing, its EBT stood at $30.5 million for Q3 2021, which was down 46.96% from $57.5 million recorded in Q2 2021.
  • Neurocrine Biosciences' 5-year EBT high stood at $83.2 million for Q2 2020, and its period low was -$102.6 million during Q1 2019.
  • Moreover, its 3-year median value for EBT was $38.8 million (2019), whereas its average is $22.7 million.
  • In the last 5 years, Neurocrine Biosciences' EBT crashed by 293.66% in 2017 and then soared by 981.11% in 2019.
  • Over the past 5 years, Neurocrine Biosciences' EBT (Quarterly) stood at $6.9 million in 2017, then soared by 172.82% to $18.8 million in 2018, then spiked by 105.46% to $38.6 million in 2019, then crashed by 197.77% to -$57.1 million in 2020, then surged by 153.42% to $30.5 million in 2021.
  • Its EBT was $30.5 million in Q3 2021, compared to $57.5 million in Q2 2021 and $27.2 million in Q1 2021.